Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Early notable gainers among liquid option names on November 26th » 09:55
11/26/21
11/26
09:55
11/26/21
09:55
MRNA

Moderna

$320.50 /

+47.23 (+17.28%)

, PFE

Pfizer

$53.73 /

+2.83 (+5.56%)

, WST

West Pharmaceutical

$453.53 /

+19.985 (+4.61%)

, DHR

Danaher

$327.45 /

+12.02 (+3.81%)

, TMO

Thermo Fisher

$660.99 /

+27.98 (+4.42%)

Notable gainers among…

Notable gainers among liquid option names this morning include Moderna (MRNA) $330.46 +57.07, Pfizer (PFE) $54.50 +3.61, West Pharmaceutical (WST) $454.08 +20.36, Danaher (DHR) $329.81 +14.33, and Thermo Fisher (TMO) $660.62 +27.62.

ShowHide Related Items >><<
WST West Pharmaceutical
$453.53 /

+19.985 (+4.61%)

TMO Thermo Fisher
$660.99 /

+27.98 (+4.42%)

PFE Pfizer
$53.73 /

+2.83 (+5.56%)

MRNA Moderna
$320.50 /

+47.23 (+17.28%)

DHR Danaher
$327.45 /

+12.02 (+3.81%)

MRNA Moderna
$320.50 /

+47.23 (+17.28%)

11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
11/12/21 Piper Sandler
Piper keeps $348 target on Moderna after solid tumor data
11/08/21 Wolfe Research
Moderna initiated with an Outperform at Wolfe Research
PFE Pfizer
$53.73 /

+2.83 (+5.56%)

11/26/21 Citi
Pfizer can deliver novel vaccine within 100 days of sequencing, says Citi
11/26/21 Mizuho
Pfizer data on vupanorsen is mixed, says Mizuho
11/24/21 Truist
Pfizer price target raised to $58 from $43 at Truist
11/24/21 Oppenheimer
Enanta price target raised to $73 from $55 at Oppenheimer
WST West Pharmaceutical
$453.53 /

+19.985 (+4.61%)

DHR Danaher
$327.45 /

+12.02 (+3.81%)

11/26/21 Benchmark
Recent deals highlight value in ImmunoPrecise shares, says Benchmark
10/25/21 Argus
Danaher well positioned to benefit from development of new medicines, says Argus
10/22/21 Baird
Danaher price target raised to $340 from $305 at Baird
10/22/21 Citi
Danaher price target raised to $370 from $345 at Citi
TMO Thermo Fisher
$660.99 /

+27.98 (+4.42%)

10/28/21
Fly Intel: Top five analyst initiations
10/28/21 SVB Leerink
Thermo Fisher price target raised to $685 from $675 at SVB Leerink
10/28/21 Morgan Stanley
Thermo Fisher resumed with an Overweight at Morgan Stanley
10/28/21 Baird
Thermo Fisher price target raised to $657 from $635 at Baird
WST West Pharmaceutical
$453.53 /

+19.985 (+4.61%)

TMO Thermo Fisher
$660.99 /

+27.98 (+4.42%)

PFE Pfizer
$53.73 /

+2.83 (+5.56%)

MRNA Moderna
$320.50 /

+47.23 (+17.28%)

DHR Danaher
$327.45 /

+12.02 (+3.81%)

PFE Pfizer
$53.73 /

+2.83 (+5.56%)

MRNA Moderna
$320.50 /

+47.23 (+17.28%)

TMO Thermo Fisher
$660.99 /

+27.98 (+4.42%)

MRNA Moderna
$320.50 /

+47.23 (+17.28%)

DHR Danaher
$327.45 /

+12.02 (+3.81%)

WST West Pharmaceutical
$453.53 /

+19.985 (+4.61%)

TMO Thermo Fisher
$660.99 /

+27.98 (+4.42%)

PFE Pfizer
$53.73 /

+2.83 (+5.56%)

MRNA Moderna
$320.50 /

+47.23 (+17.28%)

DHR Danaher
$327.45 /

+12.02 (+3.81%)

Options
Early notable gainers among liquid option names on November 16th » 09:55
11/16/21
11/16
09:55
11/16/21
09:55
HD

Home Depot

$380.17 /

+9.11 (+2.46%)

, WST

West Pharmaceutical

$431.32 /

+9.04 (+2.14%)

, LOW

Lowe's

$239.79 /

+4.815 (+2.05%)

, ETSY

Etsy

$276.60 /

+3.92 (+1.44%)

, DHR

Danaher

$303.32 /

+3.71 (+1.24%)

Notable gainers among…

Notable gainers among liquid option names this morning include Home Depot (HD) $385.72 +14.64, West Pharmaceutical (WST) $435.34 +12.88, Lowe's (LOW) $241.44 +6.52, Etsy (ETSY) $279.01 +6.29, and Danaher (DHR) $305.93 +6.25.

ShowHide Related Items >><<
WST West Pharmaceutical
$431.32 /

+9.04 (+2.14%)

LOW Lowe's
$239.79 /

+4.815 (+2.05%)

HD Home Depot
$380.17 /

+9.11 (+2.46%)

ETSY Etsy
$276.60 /

+3.92 (+1.44%)

DHR Danaher
$303.32 /

+3.71 (+1.24%)

HD Home Depot
$380.17 /

+9.11 (+2.46%)

11/08/21 Wells Fargo
Home Depot price target raised to $400 from $365 at Wells Fargo
10/08/21
Fly Intel: Top five analyst downgrades
10/08/21 Loop Capital
Home Depot downgraded to Hold at Loop Capital on supply chain issues, inflation
10/08/21 Loop Capital
Home Depot downgraded to Hold from Buy at Loop Capital
WST West Pharmaceutical
$431.32 /

+9.04 (+2.14%)

LOW Lowe's
$239.79 /

+4.815 (+2.05%)

11/08/21 Wells Fargo
Lowe's price target raised to $260 from $230 at Wells Fargo
10/08/21 Loop Capital
Lowe's downgraded to Hold from Buy at Loop Capital
10/08/21 Loop Capital
Lowe's downgraded to Hold from Buy at Loop Capital
ETSY Etsy
$276.60 /

+3.92 (+1.44%)

11/04/21 Oppenheimer
Etsy price target raised to $285 from $225 at Oppenheimer
11/04/21 Truist
Etsy price target raised to $274 from $215 at Truist
11/04/21 Stifel
Etsy price target raised to $265 from $230 at Stifel
11/04/21 BTIG
Etsy price target raised to $260 from $238 at BTIG
DHR Danaher
$303.32 /

+3.71 (+1.24%)

10/25/21 Argus
Danaher well positioned to benefit from development of new medicines, says Argus
10/22/21 Baird
Danaher price target raised to $340 from $305 at Baird
10/22/21 Citi
Danaher price target raised to $370 from $345 at Citi
10/14/21 Cowen
Danaher named among top large-cap picks at Cowen
WST West Pharmaceutical
$431.32 /

+9.04 (+2.14%)

LOW Lowe's
$239.79 /

+4.815 (+2.05%)

HD Home Depot
$380.17 /

+9.11 (+2.46%)

ETSY Etsy
$276.60 /

+3.92 (+1.44%)

DHR Danaher
$303.32 /

+3.71 (+1.24%)

LOW Lowe's
$239.79 /

+4.815 (+2.05%)

HD Home Depot
$380.17 /

+9.11 (+2.46%)

ETSY Etsy
$276.60 /

+3.92 (+1.44%)

LOW Lowe's
$239.79 /

+4.815 (+2.05%)

HD Home Depot
$380.17 /

+9.11 (+2.46%)

ETSY Etsy
$276.60 /

+3.92 (+1.44%)

DHR Danaher
$303.32 /

+3.71 (+1.24%)

LOW Lowe's
$239.79 /

+4.815 (+2.05%)

HD Home Depot
$380.17 /

+9.11 (+2.46%)

ETSY Etsy
$276.60 /

+3.92 (+1.44%)

DHR Danaher
$303.32 /

+3.71 (+1.24%)

Over a month ago
Earnings
West Pharmaceutical ups FY21 adjusted EPS view to $8.40-$8.50 from $8.05-$8.20 » 06:20
10/28/21
10/28
06:20
10/28/21
06:20
WST

West Pharmaceutical

$421.86 /

+1.29 (+0.31%)

Consensus $8.21. Raises…

Consensus $8.21. Raises FY21 revenue view to $2.8B-$2.81B from $2.76B-$2.79B, consensus $2.8B. The company said, "Full-year adjusted-diluted EPS guidance range includes an estimated benefit of approximately $0.19 based on current foreign currency exchange rates. This updated guidance is a reduction of $0.08, compared to a prior estimated benefit of $0.27. Net sales guidance includes an estimated full-year 2021 benefit of $55 million based on current foreign exchange rates. This updated guidance is a reduction of $25 million, compared to a prior estimated full-year benefit of $80 million."

ShowHide Related Items >><<
WST West Pharmaceutical
$421.86 /

+1.29 (+0.31%)

WST West Pharmaceutical
$421.86 /

+1.29 (+0.31%)

11/09/20 KeyBanc
West Pharmaceutical initiated with an Overweight at KeyBanc
WST West Pharmaceutical
$421.86 /

+1.29 (+0.31%)

Earnings
West Pharmaceutical reports Q3 adjusted EPS $2.06, consensus $1.80 » 06:17
10/28/21
10/28
06:17
10/28/21
06:17
WST

West Pharmaceutical

$421.86 /

+1.29 (+0.31%)

Reports Q3 revenue…

Reports Q3 revenue $706.5M, consensus $687.09M. "We had robust growth in all three of our Proprietary Products market units, led by the sales of components in our High-Value Product (HVP) portfolio," said Eric Green, president and CEO. "This quarter's strong performance came from both our base business, especially in the Biologics market unit, and COVID-19 related sales. Demand continues to grow for our premium offerings, such as NovaPure and FluroTec components, and, as a result, we are again increasing our planned capital expenditures, commencing next year, to expand HVP capacity at existing sites."

ShowHide Related Items >><<
WST West Pharmaceutical
$421.86 /

+1.29 (+0.31%)

WST West Pharmaceutical
$421.86 /

+1.29 (+0.31%)

11/09/20 KeyBanc
West Pharmaceutical initiated with an Overweight at KeyBanc
WST West Pharmaceutical
$421.86 /

+1.29 (+0.31%)

Over a quarter ago
Earnings
West Pharmaceutical reports Q2 adjusted EPS $2.46, consensus $1.74 » 06:24
07/29/21
07/29
06:24
07/29/21
06:24
WST

West Pharmaceutical

$383.73 /

+5.755 (+1.52%)

Reports Q2 revenue…

Reports Q2 revenue $723.6M, consensus $669.38M. "Our strong second quarter performance was driven by continued momentum in organic sales growth in both our base business as well as increased demand for our products associated with COVID-19 vaccines," said Eric Green, president and CEO. "Guided by our mission, our dedicated team members remain focused on meeting the increased demand for our high-value product (HVP) components. Our market-led strategy coupled with our scientific leadership and regulatory insights in primary packaging and delivery of injectable drugs have resonated with our customers, resulting in a high participation rate on newly approved molecular entities, especially large molecule therapies. Over the past year and half, we have accelerated capital spending and expanded global HVP manufacturing capacity. Based on growing future demand from our customers, we are announcing another tranche of capital spending to expand HVP capacity that we expect will be ready for production in 2022. Given the strong first half of the year, we are raising our full-year financial guidance."

ShowHide Related Items >><<
WST West Pharmaceutical
$383.73 /

+5.755 (+1.52%)

WST West Pharmaceutical
$383.73 /

+5.755 (+1.52%)

11/09/20 KeyBanc
West Pharmaceutical initiated with an Overweight at KeyBanc
10/13/20 Stephens
West Pharmaceutical initiated with an Equal Weight at Stephens
WST West Pharmaceutical
$383.73 /

+5.755 (+1.52%)

Hot Stocks
scPharmaceuticals says in alignment with FDA on FUROSCIX development » 08:03
07/01/21
07/01
08:03
07/01/21
08:03
SCPH

scPharmaceuticals

$6.11 /

+0.47 (+8.34%)

, WST

West Pharmaceutical

$359.14 /

-0.75 (-0.21%)

scPharmaceuticals (SCPH)…

scPharmaceuticals (SCPH) announced that on June 30, 2021 the Company received the minutes from its Type C meeting with the U.S. Food and Drug Administration regarding the requirements for resubmission of the FUROSCIX New Drug Application. Based on guidance the Company received during the meeting and subsequently contained within the meeting minutes, the Company is moving forward with its original plan to conduct the required bench testing for the West Pharmaceutical Services' (WST) SmartDose Gen II on-body drug delivery system that is used to deliver FUROSCIX to heart failure patients. Importantly, the FDA has not requested modifications to the device.

ShowHide Related Items >><<
SCPH scPharmaceuticals
$6.11 /

+0.47 (+8.34%)

SCPH scPharmaceuticals
$6.11 /

+0.47 (+8.34%)

12/08/20 BMO Capital
scPharmaceuticals price target lowered to $10 from $13 at BMO Capital
WST West Pharmaceutical
$359.14 /

-0.75 (-0.21%)

11/09/20 KeyBanc
West Pharmaceutical initiated with an Overweight at KeyBanc
10/13/20 Stephens
West Pharmaceutical initiated with an Equal Weight at Stephens
07/21/20 BofA
West Pharmaceutical upgraded to Buy on COVID-related tailwinds at BofA
07/21/20 BofA
West Pharmaceutical upgraded to Buy from Neutral at BofA
WST West Pharmaceutical
$359.14 /

-0.75 (-0.21%)

SCPH scPharmaceuticals
$6.11 /

+0.47 (+8.34%)

SCPH scPharmaceuticals
$6.11 /

+0.47 (+8.34%)

Conference/Events
BofA to hold a virtual conference » 09:36
05/11/21
05/11
09:36
05/11/21
09:36
ADCT

ADC Therapeutics

$22.44 /

-1.15 (-4.87%)

, ADMS

Adamas Pharmaceuticals

$4.96 /

-0.2 (-3.88%)

, AVTR

Avantor

$30.48 /

-0.725 (-2.32%)

, CCRN

Cross Country Healthcare

$17.16 /

+0.26 (+1.54%)

, FIXX

Homology Medicines

$6.39 /

-0.13 (-1.99%)

, IMTX

Immatics

$10.81 /

-0.77 (-6.65%)

, ISRG

Intuitive Surgical

$835.60 /

-21.9 (-2.55%)

, ITCI

Intra-Cellular

$35.97 /

+1.01 (+2.89%)

, JAZZ

Jazz Pharmaceuticals

$176.02 /

+1.35 (+0.77%)

, JNJ

Johnson & Johnson

$170.32 /

+1.68 (+1.00%)

, LLY

Eli Lilly

$194.82 /

-0.75 (-0.38%)

, TVTX

Travere Therapeutics

$19.78 /

-0.23 (-1.15%)

, QGEN

Qiagen

$46.90 /

-0.75 (-1.57%)

, PTCT

PTC Therapeutics

$38.88 /

-1.34 (-3.33%)

, PHG

Philips

$56.39 /

-1.016893 (-1.77%)

, SWAV

ShockWave Medical

$134.82 /

-12.73 (-8.63%)

, RLAY

Relay Therapeutics

$27.69 /

-1.8 (-6.10%)

, ZBH

Zimmer Biomet

$171.99 /

-0.575 (-0.33%)

, WST

West Pharmaceutical

$333.76 /

-0.36 (-0.11%)

, NVRO

Nevro

$155.00 /

-1.15 (-0.74%)

, HUM

Humana

$470.07 /

+5.45 (+1.17%)

, DHR

Danaher

$259.10 /

+0.8 (+0.31%)

Bank of America Merrill…

Bank of America Merrill Lynch Virtual Healthcare Conference will be held on May 11-13.

ShowHide Related Items >><<
ZBH Zimmer Biomet
$171.99 /

-0.575 (-0.33%)

TVTX Travere Therapeutics
$19.78 /

-0.23 (-1.15%)

SWAV ShockWave Medical
$134.82 /

-12.73 (-8.63%)

RLAY Relay Therapeutics
$27.69 /

-1.8 (-6.10%)

QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

PTCT PTC Therapeutics
$38.88 /

-1.34 (-3.33%)

PHG Philips
$56.39 /

-1.016893 (-1.77%)

NVRO Nevro
$155.00 /

-1.15 (-0.74%)

LLY Eli Lilly
$194.82 /

-0.75 (-0.38%)

JNJ Johnson & Johnson
$170.32 /

+1.68 (+1.00%)

JAZZ Jazz Pharmaceuticals
$176.02 /

+1.35 (+0.77%)

ITCI Intra-Cellular
$35.97 /

+1.01 (+2.89%)

ISRG Intuitive Surgical
$835.60 /

-21.9 (-2.55%)

IMTX Immatics
$10.81 /

-0.77 (-6.65%)

HUM Humana
$470.07 /

+5.45 (+1.17%)

FIXX Homology Medicines
$6.39 /

-0.13 (-1.99%)

DHR Danaher
$259.10 /

+0.8 (+0.31%)

CCRN Cross Country Healthcare
$17.16 /

+0.26 (+1.54%)

AVTR Avantor
$30.48 /

-0.725 (-2.32%)

ADMS Adamas Pharmaceuticals
$4.96 /

-0.2 (-3.88%)

ADCT ADC Therapeutics
$22.44 /

-1.15 (-4.87%)

ADCT ADC Therapeutics
$22.44 /

-1.15 (-4.87%)

04/26/21 H.C. Wainwright
ADC Therapeutics price target raised to $57 from $48 at H.C. Wainwright
03/19/21 H.C. Wainwright
ADC Therapeutics price target raised to $48 from $47 at H.C. Wainwright
12/02/20 Stifel
ADC Therapeutics initiated with a Hold at Stifel
10/29/20
Fly Intel: Top five analyst initiations
ADMS Adamas Pharmaceuticals
$4.96 /

-0.2 (-3.88%)

02/02/21 H.C. Wainwright
Adamas Pharmaceuticals price target raised to $12 from $10 at H.C. Wainwright
02/01/21 JMP Securities
Adamas settlement brings 'robust' patent exclusivity, says JMP Securities
01/28/21 Northland
Adamas Pharmaceuticals price target raised to $12.50 from $7.50 at Northland
AVTR Avantor
$30.48 /

-0.725 (-2.32%)

04/29/21 JPMorgan
Avantor price target raised to $40 from $35 at JPMorgan
04/29/21 Baird
Avantor price target raised to $36 from $32 at Baird
04/29/21 Stifel
Avantor upgraded to Buy after 'strong' Q1 report at Stifel
04/29/21 Stifel
Avantor upgraded to Buy from Hold at Stifel
CCRN Cross Country Healthcare
$17.16 /

+0.26 (+1.54%)

05/06/21 Benchmark
Cross Country Healthcare downgraded to Hold from Buy at Benchmark
03/09/21 Barrington
Barrington ups Cross Country Healthcare target to $14 after quarterly results
11/25/20 Barrington
Cross Country Healthcare target raised to $12 at Barrington after Q3 results
11/23/20 BMO Capital
BMO upgrades Cross Country Healthcare to Outperform on success of turnaround
FIXX Homology Medicines
$6.39 /

-0.13 (-1.99%)

05/07/21 Oppenheimer
Homology Medicines price target lowered to $24 from $27 at Oppenheimer
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
IMTX Immatics
$10.81 /

-0.77 (-6.65%)

03/17/21 Chardan
Immatics' early TCR platform activity signals 'notable,' says Chardan
03/17/21 SVB Leerink
Immatics price target raised to $26 from $17 at SVB Leerink
11/20/20 BofA
Immatics initiated with a Buy at BofA
09/21/20 Goldman Sachs
Immatics initiated with a Buy at Goldman Sachs
ISRG Intuitive Surgical
$835.60 /

-21.9 (-2.55%)

04/21/21 SVB Leerink
Intuitive Surgical price target raised to $860 from $825 at SVB Leerink
04/21/21 Wells Fargo
Intuitive Surgical price target raised to $892 from $879 at Wells Fargo
04/21/21 Deutsche Bank
Intuitive Surgical price target raised to $825 from $690 at Deutsche Bank
04/21/21 JPMorgan
Intuitive Surgical price target raised to $900 from $840 at JPMorgan
ITCI Intra-Cellular
$35.97 /

+1.01 (+2.89%)

12/29/20 Cantor Fitzgerald
Intra-Cellular price target raised to $54 from $53 at Cantor Fitzgerald
12/15/20
Fly Intel: Top five analyst initiations
12/15/20 BofA
Intra-Cellular initiated with a Buy at BofA
12/10/20
Fly Intel: Top five analyst initiations
JAZZ Jazz Pharmaceuticals
$176.02 /

+1.35 (+0.77%)

04/21/21 Cantor Fitzgerald
Jazz Pharmaceuticals price target raised to $198 from $185 at Cantor Fitzgerald
04/14/21 Stifel
Jazz Pharmaceuticals price target raised to $202 from $195 at Stifel
04/06/21 RBC Capital
Jazz Pharmaceuticals transferred with an Outperform at RBC Capital
04/01/21 Morgan Stanley
Jazz Pharmaceuticals price target raised to $176 from $162 at Morgan Stanley
JNJ Johnson & Johnson
$170.32 /

+1.68 (+1.00%)

05/05/21 Argus
Emergent BioSolutions downgraded to Hold from Buy at Argus
04/29/21 Wells Fargo
Boston Scientific price target raised to $50 from $42 at Wells Fargo
04/26/21 B. Riley
B. Riley reiterates Buy on Novavax, Sell on Arcturus amid vaccine developments
04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
LLY Eli Lilly
$194.82 /

-0.75 (-0.38%)

04/28/21 Mizuho
Eli Lilly price target lowered to $216 from $228 at Mizuho
04/28/21 Barclays
Eli Lilly price target lowered to $227 from $232 at Barclays
04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
TVTX Travere Therapeutics
$19.78 /

-0.23 (-1.15%)

05/07/21 BMO Capital
Travere Therapeutics price target lowered to $38 from $43 at BMO Capital
04/12/21 Wedbush
Travere Therapeutics price target lowered to $39 from $46 at Wedbush
03/02/21 BMO Capital
Travere Therapeutics price target lowered to $43 from $48 at BMO Capital
02/16/21 Barclays
Travere Therapeutics assumed with an Overweight at Barclays
QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

02/19/21 Berenberg
Qiagen price target raised to EUR 56 from EUR 52 at Berenberg
02/09/21 William Blair
Quidel, Qiagen merger would not make sense, says William Blair
02/09/21 Wells Fargo
Qiagen shares should be sold on latest merger talk, says Wells Fargo
02/09/21 Citi
Merger with Qiagen would benefit Quidel, says Citi
PTCT PTC Therapeutics
$38.88 /

-1.34 (-3.33%)

04/26/21 Credit Suisse
PTC Therapeutics assumed with a Neutral at Credit Suisse
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
PHG Philips
$56.39 /

-1.016893 (-1.77%)

04/29/21 Berenberg
Philips price target raised to EUR 52 from EUR 50 at Berenberg
04/28/21 Credit Suisse
Philips price target raised to EUR 49 from EUR 45 at Credit Suisse
04/27/21 UBS
Philips price target raised to EUR 56 from EUR 54 at UBS
03/23/21 Barclays
Philips price target raised to EUR 55 from EUR 54 at Barclays
SWAV ShockWave Medical
$134.82 /

-12.73 (-8.63%)

05/11/21 Wells Fargo
ShockWave Medical price target raised to $161 from $151 at Wells Fargo
05/11/21 BofA
ShockWave Medical upgraded to Buy at BofA after guidance hike
05/11/21 BofA
ShockWave Medical upgraded to Buy from Neutral at BofA
05/11/21 Piper Sandler
ShockWave Medical upgraded to Overweight from Neutral at Piper Sandler
RLAY Relay Therapeutics
$27.69 /

-1.8 (-6.10%)

03/29/21 JMP Securities
Relay Therapeutics price target lowered to $50 from $66 at JMP Securities
01/29/21 JPMorgan
Relay Therapeutics price target raised to $52 from $36 at JPMorgan
12/15/20 H.C. Wainwright
Relay Therapeutics price target raised to $57 from $54 at H.C. Wainwright
12/08/20 JMP Securities
Relay Therapeutics initiated with an Outperform at JMP Securities
ZBH Zimmer Biomet
$171.99 /

-0.575 (-0.33%)

05/11/21 JMP Securities
Zimmer Biomet price target raised to $195 from $180 at JMP Securities
05/05/21 Truist
Zimmer Biomet price target raised to $188 from $174 at Truist
05/05/21 Oppenheimer
Zimmer Biomet price target raised to $195 from $185 at Oppenheimer
04/09/21 Northland
Zimmer Biomet upgraded to Outperform from Market Perform at Northland
WST West Pharmaceutical
$333.76 /

-0.36 (-0.11%)

11/09/20 KeyBanc
West Pharmaceutical initiated with an Overweight at KeyBanc
10/13/20 Stephens
West Pharmaceutical initiated with an Equal Weight at Stephens
07/21/20 BofA
West Pharmaceutical upgraded to Buy on COVID-related tailwinds at BofA
07/21/20 BofA
West Pharmaceutical upgraded to Buy from Neutral at BofA
NVRO Nevro
$155.00 /

-1.15 (-0.74%)

05/06/21 Canaccord
Nevro price target raised to $225 from $217 at Canaccord
04/05/21 Piper Sandler
Nevro publication in JAMA Neurology helps add credibility, says Piper Sandler
02/25/21 Canaccord
Nevro price target raised to $217 from $203 at Canaccord
02/02/21
Fly Intel: Top five analyst initiations
HUM Humana
$470.07 /

+5.45 (+1.17%)

04/29/21 Oppenheimer
Humana price target raised to $480 from $460 at Oppenheimer
04/29/21 Mizuho
Humana price target raised to $480 from $462 at Mizuho
04/29/21 Citi
Humana price target raised to $510 from $496 at Citi
04/16/21 Stephens
Humana named a new Best Idea for 2021 at Stephens
DHR Danaher
$259.10 /

+0.8 (+0.31%)

04/26/21 Barclays
Danaher price target raised to $300 from $265 at Barclays
04/23/21 Jefferies
Danaher price target raised to $290 from $270 at Jefferies
04/23/21 Baird
Danaher price target raised to $270 from $249 at Baird
04/23/21 Wells Fargo
Danaher price target raised to $280 from $260 at Wells Fargo
ZBH Zimmer Biomet
$171.99 /

-0.575 (-0.33%)

WST West Pharmaceutical
$333.76 /

-0.36 (-0.11%)

TVTX Travere Therapeutics
$19.78 /

-0.23 (-1.15%)

SWAV ShockWave Medical
$134.82 /

-12.73 (-8.63%)

RLAY Relay Therapeutics
$27.69 /

-1.8 (-6.10%)

QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

PTCT PTC Therapeutics
$38.88 /

-1.34 (-3.33%)

PHG Philips
$56.39 /

-1.016893 (-1.77%)

NVRO Nevro
$155.00 /

-1.15 (-0.74%)

LLY Eli Lilly
$194.82 /

-0.75 (-0.38%)

JNJ Johnson & Johnson
$170.32 /

+1.68 (+1.00%)

JAZZ Jazz Pharmaceuticals
$176.02 /

+1.35 (+0.77%)

ITCI Intra-Cellular
$35.97 /

+1.01 (+2.89%)

ISRG Intuitive Surgical
$835.60 /

-21.9 (-2.55%)

IMTX Immatics
$10.81 /

-0.77 (-6.65%)

HUM Humana
$470.07 /

+5.45 (+1.17%)

FIXX Homology Medicines
$6.39 /

-0.13 (-1.99%)

DHR Danaher
$259.10 /

+0.8 (+0.31%)

CCRN Cross Country Healthcare
$17.16 /

+0.26 (+1.54%)

AVTR Avantor
$30.48 /

-0.725 (-2.32%)

ADMS Adamas Pharmaceuticals
$4.96 /

-0.2 (-3.88%)

ADCT ADC Therapeutics
$22.44 /

-1.15 (-4.87%)

  • 07
    Apr
  • 25
    Feb
  • 12
    Feb
  • 06
    Nov
  • 24
    Sep
  • 11
    Sep
  • 20
    Aug
  • 16
    Jul
  • 17
    Jun
  • 21
    May
  • 15
    May
QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

PHG Philips
$56.39 /

-1.016893 (-1.77%)

NVRO Nevro
$155.00 /

-1.15 (-0.74%)

LLY Eli Lilly
$194.82 /

-0.75 (-0.38%)

JNJ Johnson & Johnson
$170.32 /

+1.68 (+1.00%)

JAZZ Jazz Pharmaceuticals
$176.02 /

+1.35 (+0.77%)

DHR Danaher
$259.10 /

+0.8 (+0.31%)

ZBH Zimmer Biomet
$171.99 /

-0.575 (-0.33%)

SWAV ShockWave Medical
$134.82 /

-12.73 (-8.63%)

QGEN Qiagen
$46.90 /

-0.75 (-1.57%)

PTCT PTC Therapeutics
$38.88 /

-1.34 (-3.33%)

PHG Philips
$56.39 /

-1.016893 (-1.77%)

LLY Eli Lilly
$194.82 /

-0.75 (-0.38%)

JNJ Johnson & Johnson
$170.32 /

+1.68 (+1.00%)

JAZZ Jazz Pharmaceuticals
$176.02 /

+1.35 (+0.77%)

ISRG Intuitive Surgical
$835.60 /

-21.9 (-2.55%)

IMTX Immatics
$10.81 /

-0.77 (-6.65%)

HUM Humana
$470.07 /

+5.45 (+1.17%)

FIXX Homology Medicines
$6.39 /

-0.13 (-1.99%)

CCRN Cross Country Healthcare
$17.16 /

+0.26 (+1.54%)

ZBH Zimmer Biomet
$171.99 /

-0.575 (-0.33%)

TVTX Travere Therapeutics
$19.78 /

-0.23 (-1.15%)

RLAY Relay Therapeutics
$27.69 /

-1.8 (-6.10%)

LLY Eli Lilly
$194.82 /

-0.75 (-0.38%)

JNJ Johnson & Johnson
$170.32 /

+1.68 (+1.00%)

ISRG Intuitive Surgical
$835.60 /

-21.9 (-2.55%)

DHR Danaher
$259.10 /

+0.8 (+0.31%)

Earnings
West raises FY21 adjusted EPS view to $6.95-$7.10 from $6.00-$6.15 » 06:17
04/29/21
04/29
06:17
04/29/21
06:17
WST

West Pharmaceutical

$322.88 /

+2.26 (+0.70%)

Consensus $6.15. Raises…

Consensus $6.15. Raises FY21 revenue view to $2.63B-$2.66B, consensus $2.58B. The company said, "Full-year adjusted-diluted EPS guidance range includes an estimated benefit of approximately $0.23 based on current foreign currency exchange rates. The revised guidance includes a $0.15 EPS positive impact from first-quarter tax benefits from stock-based compensation. For the remainder of the year, our EPS guidance range assumes a tax rate of 23% and does not include potential tax benefits from stock-based compensation. Any tax benefits associated with stock-based compensation beyond those recorded in the first-quarter 2021 would provide a positive adjustment to our full-year EPS guidance."

ShowHide Related Items >><<
WST West Pharmaceutical
$322.88 /

+2.26 (+0.70%)

11/09/20 KeyBanc
West Pharmaceutical initiated with an Overweight at KeyBanc
10/13/20 Stephens
West Pharmaceutical initiated with an Equal Weight at Stephens
07/21/20 BofA
West Pharmaceutical upgraded to Buy on COVID-related tailwinds at BofA
07/21/20 BofA
West Pharmaceutical upgraded to Buy from Neutral at BofA
WST West Pharmaceutical
$322.88 /

+2.26 (+0.70%)

Earnings
West Pharmaceutical reports Q1 adjusted EPS $2.05, consensus $1.43 » 06:14
04/29/21
04/29
06:14
04/29/21
06:14
WST

West Pharmaceutical

$322.88 /

+2.26 (+0.70%)

Reports Q1 revenue…

Reports Q1 revenue $670.7M, consensus $611.39M. All three market units had double-digit organic sales growth, led by performance in the Biologics market unit. "We delivered another solid performance in the first quarter with strong organic sales growth from both our base business as well as increased demand for our products associated with COVID-19 vaccines," said Eric Green, president and CEO. "I am proud of the relentless focus and consistent execution of our global team members to deliver critical components and solutions during these times. With a strong start to the year, we are raising our full-year financial guidance. West will continue to play an integral role with our customers as they develop and bring new medicines to the market for a brighter future."

ShowHide Related Items >><<
WST West Pharmaceutical
$322.88 /

+2.26 (+0.70%)

11/09/20 KeyBanc
West Pharmaceutical initiated with an Overweight at KeyBanc
10/13/20 Stephens
West Pharmaceutical initiated with an Equal Weight at Stephens
07/21/20 BofA
West Pharmaceutical upgraded to Buy on COVID-related tailwinds at BofA
07/21/20 BofA
West Pharmaceutical upgraded to Buy from Neutral at BofA
WST West Pharmaceutical
$322.88 /

+2.26 (+0.70%)

Earnings
West Pharmaceutical sees FY21 EPS $6.00-$6.15, consensus $5.12 » 06:16
02/18/21
02/18
06:16
02/18/21
06:16
WST

West Pharmaceutical

$293.88 /

-1.7 (-0.58%)

Sees FY21 revenue…

Sees FY21 revenue $2.5B-$2.53B, consensus $2.35B. Sees FY21 capital spending $230M-$240M.

ShowHide Related Items >><<
WST West Pharmaceutical
$293.88 /

-1.7 (-0.58%)

WST West Pharmaceutical
$293.88 /

-1.7 (-0.58%)

11/09/20 KeyBanc
West Pharmaceutical initiated with an Overweight at KeyBanc
10/13/20 Stephens
West Pharmaceutical initiated with an Equal Weight at Stephens
07/21/20 BofA
West Pharmaceutical upgraded to Buy on COVID-related tailwinds at BofA
07/21/20 BofA
West Pharmaceutical upgraded to Buy from Neutral at BofA
WST West Pharmaceutical
$293.88 /

-1.7 (-0.58%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.